Company profile

IOVANCE BIOTHERAPEUTICS, INC.

NASDAQ:IOVABiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (3)

AssetStageRevenueTrialsStatus
AMTAGVIapproved$90.7MQ2 202610approved
PROLEUKINapproved$8.6MQ2 20260—
IOV-2001phase1—1no active trials

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (15)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT07743723phase1_2not_yet_recruiting2026-09-012034-03-01Iovance Biotherapeutics, Inc.A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT06481592phase2recruiting2024-10-292028-05-01Iovance Biotherapeutics, Inc.A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT07288203phase2active_not_recruiting2025-11-282027-12-01Iovance Biotherapeutics, Inc.A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07741877phase2recruiting2026-10-022033-09-01Iovance Biotherapeutics, Inc.A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
NCT05361174phase1_2recruiting2022-07-202027-09-01Iovance Biotherapeutics, Inc.A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

FDA applications (2)

ApplicationApprovedTypeApplicantProducts
BLA 1257732024-02-16BLAIOVANCE BIOTHERAPEUTICS, INC.
BLA 1032931992-05-05BLAIOVANCE BIOTHERAPEUTICS MANUFACTURING LLC